Brought to you by 
Horizon Pharma nets $46mm through its IPO
14 Nov 2011
Executive Summary
A year after filing to go public, Horizon Pharma Inc. (developing therapeutics for pain and inflammation disorders) has completed its IPO, netting $46mm through the sale of 5.5mm common shares at $9, less than the $10-12 range it gave earlier this month.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon Pharma nets $46mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice